m6A Target Gene Information
General Information of the m6A Target Gene (ID: M6ATAR00030)
Full List of m6A Methylation Regulator of This Target Gene and Corresponding Disease/Drug Response(s)
hsa-mir-181b-1
can be regulated by the following regulator(s), and cause disease/drug response(s). You can browse detail information of regulator(s) or disease/drug response(s).
Browse Regulator
Browse Disease
RNA demethylase ALKBH5 (ALKBH5) [ERASER]
| In total 1 item(s) under this regulator | ||||
| Experiment 1 Reporting the m6A Methylation Regulator of This Target Gene | [1] | |||
| Response Summary | ALKBH5 is an anti-tumor factor or a pro-apoptotic factor, acting at least partially by suppressing YAP expression through dual mechanisms with direct m6A methylation of YAP and indirect downregulation of YAP level due to methylation of hsa-mir-181b-1. Further results revealed that m6A methylated pre-miR-181b-1 was subsequently recognized by m6A-binding protein YTHDF2 to mediate RNA degradation. However, methylated YAP transcripts were recognized by YTHDF1 to promote its translation. ALKBH5 overexpression was considered a new approach of replacement therapy for osteosarcoma treatment. | |||
| Target Regulation | Down regulation | |||
| Responsed Disease | Osteosarcoma | ICD-11: 2B51 | ||
| Cell Process | Cell growth | |||
| Cell migration | ||||
| Cell invasion | ||||
| Cell apoptosis | ||||
| In-vitro Model | U2OS | Osteosarcoma | Homo sapiens | CVCL_0042 |
| In-vivo Model | Three-week-old BABL/c female nude mice were randomized into three groups. 5 × 106 143B cells were subcutaneously injected in mice, and the tumor volume was assessed every 2 weeks. Eight weeks after injection, the animals were killed. The xenograft tumors were harvested and the tumor volumes were calculated by the standard formula: length × width2/2. | |||
YTH domain-containing family protein 2 (YTHDF2) [READER]
| In total 1 item(s) under this regulator | ||||
| Experiment 1 Reporting the m6A Methylation Regulator of This Target Gene | [1] | |||
| Response Summary | ALKBH5 is an anti-tumor factor or a pro-apoptotic factor, acting at least partially by suppressing YAP expression through dual mechanisms with direct m6A methylation of YAP and indirect downregulation of YAP level due to methylation of hsa-mir-181b-1. Further results revealed that m6A methylated pre-miR-181b-1 was subsequently recognized by m6A-binding protein YTHDF2 to mediate RNA degradation. However, methylated YAP transcripts were recognized by YTHDF1 to promote its translation. ALKBH5 overexpression was considered a new approach of replacement therapy for osteosarcoma treatment. | |||
| Target Regulation | Down regulation | |||
| Responsed Disease | Osteosarcoma | ICD-11: 2B51 | ||
| Cell Process | Cell growth | |||
| Cell migration | ||||
| Cell invasion | ||||
| Cell apoptosis | ||||
| In-vitro Model | U2OS | Osteosarcoma | Homo sapiens | CVCL_0042 |
| In-vivo Model | Three-week-old BABL/c female nude mice were randomized into three groups. 5 × 106 143B cells were subcutaneously injected in mice, and the tumor volume was assessed every 2 weeks. Eight weeks after injection, the animals were killed. The xenograft tumors were harvested and the tumor volumes were calculated by the standard formula: length × width2/2. | |||
Osteosarcoma [ICD-11: 2B51]
| In total 2 item(s) under this disease | ||||
| Experiment 1 Reporting the m6A-centered Disease Response | [1] | |||
| Response Summary | ALKBH5 is an anti-tumor factor or a pro-apoptotic factor, acting at least partially by suppressing YAP expression through dual mechanisms with direct m6A methylation of YAP and indirect downregulation of YAP level due to methylation of hsa-mir-181b-1. Further results revealed that m6A methylated pre-miR-181b-1 was subsequently recognized by m6A-binding protein YTHDF2 to mediate RNA degradation. However, methylated YAP transcripts were recognized by YTHDF1 to promote its translation. ALKBH5 overexpression was considered a new approach of replacement therapy for osteosarcoma treatment. | |||
| Responsed Disease | Osteosarcoma [ICD-11: 2B51] | |||
| Target Regulator | RNA demethylase ALKBH5 (ALKBH5) | ERASER | ||
| Target Regulation | Down regulation | |||
| Cell Process | Cell growth | |||
| Cell migration | ||||
| Cell invasion | ||||
| Cell apoptosis | ||||
| In-vitro Model | U2OS | Osteosarcoma | Homo sapiens | CVCL_0042 |
| In-vivo Model | Three-week-old BABL/c female nude mice were randomized into three groups. 5 × 106 143B cells were subcutaneously injected in mice, and the tumor volume was assessed every 2 weeks. Eight weeks after injection, the animals were killed. The xenograft tumors were harvested and the tumor volumes were calculated by the standard formula: length × width2/2. | |||
| Experiment 2 Reporting the m6A-centered Disease Response | [1] | |||
| Response Summary | ALKBH5 is an anti-tumor factor or a pro-apoptotic factor, acting at least partially by suppressing YAP expression through dual mechanisms with direct m6A methylation of YAP and indirect downregulation of YAP level due to methylation of hsa-mir-181b-1. Further results revealed that m6A methylated pre-miR-181b-1 was subsequently recognized by m6A-binding protein YTHDF2 to mediate RNA degradation. However, methylated YAP transcripts were recognized by YTHDF1 to promote its translation. ALKBH5 overexpression was considered a new approach of replacement therapy for osteosarcoma treatment. | |||
| Responsed Disease | Osteosarcoma [ICD-11: 2B51] | |||
| Target Regulator | YTH domain-containing family protein 2 (YTHDF2) | READER | ||
| Target Regulation | Down regulation | |||
| Cell Process | Cell growth | |||
| Cell migration | ||||
| Cell invasion | ||||
| Cell apoptosis | ||||
| In-vitro Model | U2OS | Osteosarcoma | Homo sapiens | CVCL_0042 |
| In-vivo Model | Three-week-old BABL/c female nude mice were randomized into three groups. 5 × 106 143B cells were subcutaneously injected in mice, and the tumor volume was assessed every 2 weeks. Eight weeks after injection, the animals were killed. The xenograft tumors were harvested and the tumor volumes were calculated by the standard formula: length × width2/2. | |||
Full List of Crosstalk(s) between m6A Modification and Epigenetic Regulation Related to This Regulator
RNA modification
m6A Regulator: RNA demethylase ALKBH5 (ALKBH5)
| In total 1 item(s) under this m6A regulator | ||
| Crosstalk ID: M6ACROT00678 | ||
| Epigenetic Regulator | Fat mass and obesity-associated protein (FTO) | |
| Regulated Target | Metastasis associated lung adenocarcinoma transcript 1 (MALAT1) | |
| Crosstalk relationship | m6Am → m6A | |
Non-coding RNA
m6A Regulator: RNA demethylase ALKBH5 (ALKBH5)
| In total 1 item(s) under this m6A regulator | ||
| Crosstalk ID: M6ACROT05466 | ||
| Epigenetic Regulator | hsa-mir-181b-1 | |
| Regulated Target | Transcriptional coactivator YAP1 (YAP1) | |
| Crosstalk relationship | m6A → ncRNA | |
| Disease | Osteosarcoma | |
m6A Regulator: YTH domain-containing family protein 2 (YTHDF2)
| In total 1 item(s) under this m6A regulator | ||
| Crosstalk ID: M6ACROT05467 | ||
| Epigenetic Regulator | hsa-mir-181b-1 | |
| Regulated Target | Transcriptional coactivator YAP1 (YAP1) | |
| Crosstalk relationship | m6A → ncRNA | |
| Disease | Osteosarcoma | |